Evidence map›Paper›PMID 39891678›Full record

ArticlePediatric nephrology (Berlin, Germany)2025

Characteristics of patients with autosomal polycystic kidney disease reaching kidney failure by age 40.

Stijn Wigerinck, Pieter Schellekens, Byron H Smith, Christian Hanna, Angelique Dachy, Maroun Chedid, Abdul Hamid Borghol, Sarah R Senum, Detlef Bockenhauer, Peter C Harris and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. KDIGO 2025 ADPKD guideline through pediatric eyes.Pediatric nephrology (Berlin, Germany) · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stijn WigerinckPKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Pieter SchellekensPKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Byron H SmithDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Christian HannaDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Angelique DachyPKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Maroun ChedidDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Abdul Hamid BorgholDivision of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA.
Sarah R SenumDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Detlef BockenhauerPKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Peter C HarrisDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Francois JouretDivision of Nephrology, University of Liège Hospital, Liège, Belgium.
Bert BammensPKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Fouad T ChebibDivision of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA.
Djalila MekahliPKD Research Group, Laboratory of Ion Channel Research, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. djalila.mekahli@uzleuven.be.ORCID 0000-0003-0954-6088

Funding

ADPKD:Disease Spectrum &Genotype-Phenotype CorrelationsR01DK058816 · NIDDK · MAYO CLINIC ROCHESTER · PI Peter C. Harris · 2001 to 2026
$11.3M
Fonds Wetenschappelijk Onderzoek 1804123NFonds Wetenschappelijk Onderzoek G060623NFonds Wetenschappelijk Onderzoek G0C8920NNIDDK NIH HHS R01 DK058816
6 · The paper itself

Abstract

backgroundAutosomal dominant polycystic kidney disease (ADPKD) demonstrates broad genetic and phenotypic variability, with kidney failure (KF) occurring across a wide age spectrum. Despite several predictor tools, there remains a need to identify factors associated with rapid disease progression. This study describes the phenotypic characteristics of a multicentric cohort experiencing early-onset KF by age 40.

methodsThis retrospective, multicenter cohort study analyzed longitudinal data of rapidly progressive ADPKD patients (n = 199). The prevalence of established risk factors was compared to nine existing ADPKD cohorts (n

resultsThe median age at ADPKD diagnosis was 22.3 years (IQR, 16.5-28.6) and median age of KF was 35.6 years (31.7-38.0). Hypertension was observed in 68.1% of cases, with early-onset hypertension being more common among those with accelerated progression towards KF. Urological events were present in 60.1% of cases, with a high burden of gross hematuria (30.4%). Existing ADPKD cohorts had a mean age of 45.5 years, with weighted prevalences of hypertension (71.1%), kidney stones (22.4%), hematuria (22.9%), and urinary tract infections (22.8%). Extrarenal manifestations were less prevalent compared to other ADPKD cohorts.

conclusionThis study outlines a cohort of ADPKD patients with accelerated disease progression, reaching KF before age 40. Hypertension and urological events were highly prevalent at a young age, emphasizing the importance of early and regular blood pressure monitoring.

Indexed as

HypertensionPolycystic Kidney, Autosomal DominantRenal InsufficiencyAdolescentAdultAge of OnsetDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedPrevalenceRetrospective StudiesRisk FactorsYoung AdultADPKDAutosomal polycystic kidney diseaseEarly onset kidney failureHypertensionRapid progression clinical biomarkers

Identifiers

PMID39891678
PMCPMC12336910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.